Phytochemical Name : Magnoflorine

Properties Information
PhytoCAT-ID PhytoCAT-32
Phytochemical name or plant extracts Magnoflorine
PMID 32325867
Literature evidence Magnoflorine in combination with cisplatin at a fixed ratio of 1:1 augmented their anticancer action and yielded synergistic or additive pharmacological interactions by means of isobolographic method, therefore combined therapy using these two active agents can be a promising chemotherapy regimen in the treatment of some types of breast, lung, rhabdomyosarcoma, and glioblastoma cancers.
IUPAC name (6aS)-2,10-dimethoxy-6,6-dimethyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinolin-6-ium-1,11-diol
Phytochemicals’ class or type of plant extracts Aporphine alkaloid
Source of phytochemicals or plant Extracts Berberidaceae, Magnoliaceae, Menispermaceae, or Papaveraceae botanical families Berberis cretica
Geographical availability Berberis cretica - Cyprus, East Aegean Is., Greece, Kriti, Turkey
Plant parts Root
Other cancers Breast cancer, Glioma, Lung cancer, Myosarcoma
Target gene or protein NA
Gene or Protein evidence NA
Target pathways AKT/mTOR and p38 signaling pathways
IC50 187.32 µg/mL against MDA-MB-468
Potency MGN in high doses inhibits proliferation, induces apoptosis, and inhibits cell cycle in S/G2 phases in a dose-dependent manner.
Cell line/ mice model NCI-H1299, MDA-MB-468, T98G , TE671
Additional information  MGN seems to be a promising anti-cancer compound in therapy of some types of lung, breast, glioma, and rhabdomyosarcoma cancers, for which current standard therapies are limited or have severe strong side effects. Magnoflorine improves sensitivity to doxorubicin (DOX) of breast cancer cells via inducing apoptosis and autophagy through AKT/mTOR and p38 signaling pathways.
PubChem ID 73337
Additional PMIDs 31707337 33182753
Additional sources of information https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:106572-1
Safety NA